Louisiana Department of Health

**Medicaid Pharmaceutical and Therapeutics Committee**

**TOP$ Virtual Review**

**Via Videoconferencing**

**May 7, 2021**

**9:00 AM**

**DRAFT**

## Call to Order……………………………..……………………….….............Marty McKay

1. Parliamentary Business …………………………………………………. ….Marty McKay
   1. Introduction of Members/Roll Call
   2. Attendance/Additional Meetings
2. VII. rles Castilley Expenditures with all dosage forms P & T Committee Review Virtual Process……….....………HindAA.A. Douiki/Melwyn Wendt
3. Reports…………………………………………………………..………....Melwyn Wendt

A. Prior Authorization Monthly Report

B. PDL Reflecting Fall 2021 Recommendations

C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – December 16, 2020

1. New Business.....................................................................................................Hind Douiki
   1. Explanation of TOP$, Monographs and Cost Sheets
   2. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
2. Acne Agents, Topical
3. Analgesics, Narcotics Long
4. Analgesics, Narcotics Short
5. Androgenic Agents
6. Angiotensin Modulator Combinations
7. Angiotensin Modulators
8. Antibiotics, GI
9. Antibiotics, Inhaled
10. Antibiotics, Topical
11. Antibiotics, Vaginal
12. Anticoagulants
13. Antiemetic/Antivertigo Agents
14. Antifungals, Oral
15. Antifungals, Topical
16. Antimigraine Agents, Other
17. Antimigraine Agents, Triptans
18. Antiparasitics, Topical
19. Antivirals, Oral
20. Antivirals, Topical
21. Beta-Blockers
22. Bladder Relaxant Preparations
23. Bone Resorption Suppression and Related Agents
24. BPH Treatments
25. Calcium Channel Blockers
26. Cephalosporins and Related Antibiotics
27. Cystic Fibrosis, Oral
28. Fluoroquinolones, Oral
29. GI Motility, Chronic
30. Glucagon Agents – New
31. Growth Factors - New
32. Growth Hormone
33. H. Pylori Treatment
34. HAE Treatments – New
35. HIV / AIDS - New
36. Hypoglycemics, Alpha-Glucosidase Inhibitors
37. Hypoglycemics, Incretin Mimetics/Enhancers
38. Hypoglycemics, Insulin and Related Agents
39. Hypoglycemics, Meglitinides
40. Hypoglycemics, Metformins
41. Hypoglycemics, SGLT2
42. Hypoglycemics, Sulfonylureas
43. Hypoglycemics, TZD
44. Immunosuppressives, Oral
45. Lincosamides/Oxazolidinones/Streptogramins
46. Lipotropics, Other
47. Lipotropics, Statins
48. Macrolides/Ketolides
49. Multiple Sclerosis Agents
50. Nitrofuran Derivatives
51. Opiate Dependence Treatments
52. PAH Agents, Oral and Inhaled
53. Pancreatic Enzymes
54. Pediatric Vitamin Preparations
55. Phosphate Binders
56. Pituitary Suppressive Agents, LHRH
57. Platelet Aggregation Inhibitors
58. Pleuromutilins – New
59. Potassium Binders - New
60. Proton Pump Inhibitors
61. Sinus Node Inhibitors
62. Skeletal Muscle Relaxants
63. Tetracyclines
64. Ulcerative Colitis Agents
65. Uterine Disorder Treatments
66. Vasodilators, Coronary

C. Hepatitis C Agents

1. New & Other Single Drug Reviews………………….……………..………...Hind Douiki
2. Antipsoriatics, Topical – Wynzora®
3. Anticonvulsants – Felbatol® Suspension (Oral)
4. Anticonvulsants - Felbamate Suspension (Oral)
5. Colony Stimulating Factors – Nyvepria® (Subcutaneous)
6. Cytokine and CAM Antagonists – Xeljanz® Solution (Oral)
7. Glucocorticoids, Oral – Alkindi® Sprinkle
8. Hemophilia Treatment – Sevenfact® (Intraven)
9. Methotrexate – Reditrex® Syringe (Subcutaneous)
10. NSAIDS - Ibupak® Kit (Oral)
11. NSAIDS – Venngel® One Kit (Topical)
12. Oncology, Oral – Lung - Tepmetko® (Oral)
13. Oncology, Oral – Prostate - Orgovyx® (Oral)
14. Ophthalmics, Anti-Inflammatory/Immunomodulator – Eysuis®
15. Sedative Hypnotics – Hetlioz LQ® (Oral)
16. Steroids, Topical, Very High – Impeklo® Lotion
17. Steroids, Topical, Very High – Clobetavix® Kit
18. Other Business
19. Next Steps

A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

1. Next Meeting Date – Wednesday, October/November 2021
2. Public Testimony